TDB-DST signs agreement with Peptris for ₹86 crore RDI support to accelerate AI-driven drug discovery and development
Worth reading — New development — a Prelims-style fact (scheme, body, law, agreement or report), no past question yet.
2-minute summary
The Technology Development Board (TDB) under the Department of Science & Technology (DST) has signed a landmark agreement with Peptris to provide ₹86 crore in R&D support. This financial backing aims to accelerate AI-driven drug discovery and development in India. By leveraging advanced artificial intelligence models, the initiative seeks to drastically reduce the time and cost associated with traditional pharmaceutical research, moving molecules from conceptual discovery to preclinical stages faster. This collaboration underlines India's strategic push towards deep-tech innovation, biomedical self-reliance, and public-private partnerships in critical science sectors.
Why it's in the news
The Technology Development Board (TDB) signed a financial assistance agreement worth ₹86 crore with Peptris to boost AI-driven pharmaceutical research and drug discovery.
Facts to remember
- The Technology Development Board (TDB) operates under the Department of Science & Technology (DST).
- The agreement with Peptris provides ₹86 crore in R&D support.
- The primary focus of the funding is AI-driven drug discovery and development.
Background and context
The Technology Development Board (TDB) is a statutory body established under the Technology Development Board Act, 1995. Its core mandate is to promote the development and commercialisation of indigenous technology and adapt imported technology for wider application in India. In recent years, the Indian government has systematically expanded its focus on deep-tech domains, including artificial intelligence, biotechnology, and quantum computing. Drug discovery traditionally involves high failure rates, massive capital investments, and timelines spanning over a decade. Integrating artificial intelligence and machine learning into molecular screening and design represents a paradigm shift, enabling computational simulations to identify viable drug candidates in fractions of traditional timelines. Public funding mechanisms like TDB play a catalytic role in bridging the 'valley of death' that early-stage deep-tech start-ups frequently encounter before reaching commercial viability.
Government schemes
- Technology Development Board (TDB) Funding Scheme — Provides financial assistance to industrial concerns and start-ups for commercialising indigenous technologies or adapting imported innovations.
Mains practice: Examine the significance of integrating artificial intelligence into pharmaceutical research and the role of public financial agencies in scaling indigenous deep-tech innovations in India.
Introduction
Artificial intelligence (AI) is fundamentally transforming pharmaceutical research by compressing the traditional drug discovery timeline from over a decade to mere months. The recent ₹86 crore R&D support agreement between the Technology Development Board (TDB) and Peptris highlights India's strategic intent to capture leadership in AI-driven healthcare solutions.
Dimensions of AI-Driven Drug Discovery
• Computational Efficiency: AI algorithms drastically reduce attrition rates in drug candidate selection by predicting molecular interactions, toxicity, and pharmacokinetic profiles virtually before wet-lab synthesis.
• Cost Optimisation: Traditional drug development costs billions; AI-driven pipelines lower capital entry barriers, making targeted therapeutics for neglected tropical diseases economically viable.
• Deep-Tech Start-up Ecosystem: Initiatives backed by the Technology Development Board Act, 1995, provide critical venture funding that helps start-ups cross the 'valley of death' in deep-tech sectors.
• Biomedical Self-Reliance: Fostering domestic intellectual property in molecular design reduces India's historical dependence on foreign patented compounds and aligns with the National Biotechnology Development Strategy objectives.
Way Forward
• Establish robust ethical guidelines and regulatory frameworks specifically for AI-generated medical compounds under the Central Drugs Standard Control Organisation (CDSCO).
• Expand supercomputing infrastructure through the National Supercomputing Mission (NSM) to provide dedicated computational clusters for biotech start-ups.
• Foster structured academia-industry linkages between public research laboratories (CSIR/ICMR) and AI-focused private enterprises.
Conclusion
Integrating artificial intelligence into biomedical research is vital for achieving Atmanirbhar Bharat in health tech. Targeted public financing combined with robust data governance will position India as a global hub for next-generation drug discovery.
Prelims practice questions
Q1. Consider the following statements regarding the Technology Development Board (TDB): 1. It is a statutory body established under an Act of Parliament enacted in 1995. 2. It functions under the administrative control of the Ministry of Health and Family Welfare. 3. Its primary mandate is to provide financial assistance for commercialising indigenous technology. How many of the above statements are correct?
- Only one
- Only two
- All three
- None
Answer: B. Statement 1 is correct because TDB is a statutory body established under the Technology Development Board Act, 1995. Statement 2 is incorrect because TDB functions under the Department of Science & Technology, Ministry of Science and Technology, not the Ministry of Health and Family Welfare. Statement 3 is correct because TDB's core mandate is accelerating the commercialisation of indigenous technology and supporting domestic R&D. Hence, only two statements are correct.
Q2. Which one of the following best describes the core objective of the recent TDB agreement with Peptris in the field of pharmaceutical research?
- To establish clinical trial facilities for traditional AYUSH medicines across rural districts
- To accelerate AI-driven drug discovery and development through targeted R&D support
- To construct bulk drug parks for manufacturing generic antibiotics under the PLI scheme
- To regulate import tariffs and intellectual property rights for foreign pharmaceutical patents
Answer: B. The TDB signed an agreement with Peptris to provide ₹86 crore in R&D support specifically for advancing AI-driven drug discovery and development. The other options refer to different government initiatives such as bulk drug parks or PLI schemes, making option B the accurate choice.
Q3. Consider the following statements: Statement I: Integrating artificial intelligence into drug discovery significantly shortens the initial molecular screening and preclinical testing phases. Statement II: AI models can simulate complex biochemical interactions and predict molecular toxicity without requiring initial laboratory synthesis for every candidate. Which one of the following is correct in respect of the above statements?
- Both Statement-I and Statement-II are correct and Statement-II explains Statement-I
- Both Statement-I and Statement-II are correct but Statement-II does not explain Statement-I
- Statement-I is correct but Statement-II is incorrect
- Statement-I is incorrect but Statement-II is correct
Answer: A. Statement I is correct because AI accelerates early-stage pharmaceutical research. Statement II is also correct and provides the exact technical explanation for why AI achieves this speedup—by performing virtual simulations of biochemical properties and toxicity, thus reducing reliance on exhaustive physical synthesis.
Revision flashcards
- What is the statutory parent legislation and establishment year of the Technology Development Board (TDB)? The Technology Development Board Act, 1995; established as a statutory body in September 1996.
- Which central government department exercises administrative control over the Technology Development Board? The Department of Science & Technology (DST), under the Ministry of Science and Technology.
- How much financial R&D support was agreed upon between TDB and Peptris in October 2026? ₹86 crore allocated to accelerate AI-driven drug discovery and development.
- What is the core focus area of the company Peptris in scientific research? AI-driven drug discovery and molecular development using advanced computational technologies.
- Why is artificial intelligence considered transformative for pharmaceutical research? It drastically reduces drug discovery timelines and R&D costs by computationally simulating molecular interactions and predicting efficacy before physical testing.